Literature DB >> 20631891

Tetrahydrobiopterin Inhibits PDGF-stimulated Migration and Proliferation in Rat Aortic Smooth Muscle Cells via the Nitric Oxide Synthase-independent Pathway.

Xiaowen Jiang1, Bokyung Kim, Haiyue Lin, Chang-Kwon Lee, Junghwan Kim, Hyun Kang, Pilyoung Lee, Seung Hyo Jung, Hwan Myung Lee, Kyung-Jong Won.   

Abstract

Tetrahydrobiopterin (BH4), an essential cofactor for nitric oxide synthase (NOS) activity, is known to play important roles in modulating both NO and superoxide production during vascular diseases such as atherosclerosis. However, the role of BH4 in functions of vascular smooth muscle cells is not fully known. In this study, we tested the effects of BH4 and dihydrobiopterin (BH2), a BH4 precursor, on migration and proliferation in response to platelet-derived growth factor-BB (PDGF-BB) in rat aortic smooth muscle cells (RASMCs). Cell migration and proliferation were measured using a Boyden chamber and a 5-bromo-2'-deoxyuridine incorporation assay, respectively, and these results were confirmed with an ex vivo aortic sprout assay. Cell viability was examined by 2,3-bis [2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide assays. BH4 and BH2 decreased PDGF-BB-induced cell migration and proliferation in a dose-dependent manner. The inhibition of cell migration and proliferation by BH4 and BH2 was not affected by pretreatment with N(G)-nitro-L-arginine methyl ester, a NOS inhibitor. Moreover, the sprout outgrowth formation of aortic rings induced by PDGF-BB was inhibited by BH4 and BH2. Cell viability was not inhibited by BH4 and BH2 treatment. The present results suggest that BH4 and BH2 may inhibit PDGF-stimulated RASMC migration and proliferation via the NOS-independent pathway. Therefore, BH4 and its derivative could be useful for the development of a candidate molecule with an NO-independent anti-atherosclerotic function.

Entities:  

Keywords:  Migration; Nitric oxide; Proliferation; Rat aortic smooth muscle cells; Tetrahydrobiopterin

Year:  2010        PMID: 20631891      PMCID: PMC2902810          DOI: 10.4196/kjpp.2010.14.3.177

Source DB:  PubMed          Journal:  Korean J Physiol Pharmacol        ISSN: 1226-4512            Impact factor:   2.016


  29 in total

Review 1.  Tetrahydrobiopterin and cardiovascular disease.

Authors:  An L Moens; David A Kass
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-08-31       Impact factor: 8.311

Review 2.  Nitric oxide and the endothelium: history and impact on cardiovascular disease.

Authors:  Gunay Yetik-Anacak; John D Catravas
Journal:  Vascul Pharmacol       Date:  2006-08-17       Impact factor: 5.773

3.  Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury.

Authors:  Chao-Hung Wang; Shu-Hong Li; Richard D Weisel; Paul W M Fedak; Agnes Hung; Ren-Ke Li; Vivek Rao; Keith Hyland; Wen-Jin Cherng; Lee Errett; Yves Leclerc; Daniel Bonneau; David A Latter; Subodh Verma
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-03-17       Impact factor: 3.619

4.  Involvement of nitric oxide in IFN-gamma-mediated reduction of microvessel smooth muscle cell proliferation.

Authors:  C S Stein; Z Fabry; S Murphy; M N Hart
Journal:  Mol Immunol       Date:  1995-09       Impact factor: 4.407

5.  Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells.

Authors:  A Sachinidis; R Locher; W Vetter; D Tatje; J Hoppe
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

6.  Tetrahydrobiopterin enhances apoptotic PC12 cell death following withdrawal of trophic support.

Authors:  P Z Anastasiadis; H Jiang; L Bezin; D M Kuhn; R A Levine
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

7.  Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo.

Authors:  C A Nichol; C L Lee; M P Edelstein; J Y Chao; D S Duch
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

Review 8.  Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease.

Authors:  Nicholas J Alp; Keith M Channon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-12-04       Impact factor: 8.311

9.  A murine model for human sepiapterin-reductase deficiency.

Authors:  Seungkyoung Yang; Young Jae Lee; Jin-Man Kim; Sean Park; Joanna Peris; Philip Laipis; Young Shik Park; Jae Hoon Chung; S Paul Oh
Journal:  Am J Hum Genet       Date:  2006-01-31       Impact factor: 11.025

10.  Diminished expression of dihydropteridine reductase is a potent biomarker for hypertensive vessels.

Authors:  Chang-Kwon Lee; Jin Soo Han; Kyung-Jong Won; Seung-Hyo Jung; Hyo-Jun Park; Hwan Myung Lee; Junghwan Kim; Young Shik Park; Hyun-Jung Kim; Pyo-Jam Park; Tae-Kyu Park; Bokyung Kim
Journal:  Proteomics       Date:  2009-11       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.